New neurocognitive\/functional morbidity at hospital discharge more likely for children with SARS-CoV-2, MIS-C with neurological manifestations<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 12, 2024 (HealthDay News) — Children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome in children (MIS-C) with severe neurological manifestations are more likely to have new neurocognitive and\/or functional morbidity at hospital discharge, according to a study published online June 10 in JAMA Network Open<\/em>.<\/p>\n Conall Francoeur, M.D.C.M., from the McGill University Health Center in Montreal, and colleagues conducted a prospective cohort study involving 3,568 patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C (83.5 and 16.5 percent, respectively) between Jan. 2, 2020, and July 31, 2021. The primary outcome was new neurocognitive and\/or functional morbidity at hospital discharge.<\/p>\n The researchers found that 18.0 and 24.8 percent of the patients with acute SARS-CoV-2 and MIS-C, respectively, had a severe neurological manifestation during hospitalization. The likelihood of having new neurocognitive or functional morbidity at hospital discharge was higher among survivors with acute SARS-CoV-2 with versus without severe neurological manifestations (27.7 versus 14.6 percent); similar findings were seen for patients with MIS-C (28.0 versus 15.5 percent). The odds of having new neurocognitive and\/or functional morbidity at hospital discharge were increased for patients with acute SARS-CoV-2 and those with MIS-C after adjustment for risk factors in those with severe neurological manifestations (odds ratios, 1.85 and 2.18, respectively).<\/p>\n “Future studies should aim to better understand the pathophysiology behind the severe neurological manifestations and to investigate the role of surveillance, treatment, and follow-up of these patients with high risk of neurocognitive and\/or functional morbidities,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n